Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Core Insights - Acrivon Therapeutics is hosting a virtual R&D event on March 25, 2025, to showcase its drug discovery capabilities and updates on its clinical studies [2][3] - The company utilizes its proprietary Acrivon Predictive Precision Proteomics (AP3) platform for developing precision oncology medicines tailored to patients' tumor sensitivities [4][5] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company focused on precision oncology, employing the AP3 platform to discover and develop drug candidates [4] - The AP3 platform generates extensive quantitative data for pathway-based drug design and response prediction, facilitating rational drug discovery and the identification of effective drug combinations [4][7] Clinical Development - Acrivon's lead candidate, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial for multiple tumor types [4] - The FDA has granted Fast Track designation for ACR-368 as a monotherapy for patients with platinum-resistant ovarian or endometrial cancer, based on OncoSignature-predicted sensitivity [4] - Acrivon is also developing ACR-2316, a selective WEE1/PKMYT1 inhibitor, aimed at enhancing single-agent activity through the activation of key cell cycle proteins [5] Key Opinion Leaders - The event will feature presentations from notable experts in gynecologic oncology, including Dr. Mansoor Raza Mirza, Dr. Robert L. Coleman, and Dr. Jesper Olsen, who will provide insights into endometrial cancer [6] Future Directions - Acrivon is advancing its proprietary AP3 Interactome platform for comprehensive analyses of drug profiling data, which supports its ongoing research programs [7]